Patents by Inventor Andrew John Barker
Andrew John Barker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7745428Abstract: Compounds of formula (I): which possess cell-cycle inhibitory activity are described.Type: GrantFiled: September 29, 2006Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: David Andrews, Andrew John Barker, Maurice Raymond Finlay, Clive Green, Clifford Jones
-
Publication number: 20090054409Abstract: Compounds of formula (I): which possess cell-cycle inhibitory activity are described.Type: ApplicationFiled: September 29, 2006Publication date: February 26, 2009Inventors: David Andrews, Andrew John Barker, Maurice Raymond Finlay, Clive Green, Clifford Jones
-
Patent number: 6953809Abstract: The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.Type: GrantFiled: July 15, 2002Date of Patent: October 11, 2005Assignee: Zeneca LimitedInventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
-
Patent number: 6897214Abstract: The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.Type: GrantFiled: May 2, 2002Date of Patent: May 24, 2005Assignee: Zeneca LimitedInventors: Andrew John Barker, Craig Johnstone
-
Publication number: 20030119830Abstract: The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.Type: ApplicationFiled: July 15, 2002Publication date: June 26, 2003Applicant: ZENECA LIMITEDInventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
-
Publication number: 20030018029Abstract: The invention concerns quinazoline derivatives of the formula I 1Type: ApplicationFiled: May 2, 2002Publication date: January 23, 2003Applicant: ZENECA LIMITEDInventors: Andrew John Barker, Craig Johnstone
-
Patent number: 6441004Abstract: The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.Type: GrantFiled: February 3, 2000Date of Patent: August 27, 2002Assignee: Zeneca LimitedInventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
-
Patent number: 6399602Abstract: The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.Type: GrantFiled: September 11, 1998Date of Patent: June 4, 2002Assignee: Zeneca LimitedInventors: Andrew John Barker, Craig Johnstone
-
Patent number: 6288103Abstract: The invention concerns pharmaceutically useful indoles of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, as well as pharmaceutical compositions containing them. The novel compounds possess inhibitory activity against monocyte chemoattractant protein-1 (MCP-1). The invention further concerns the use of such indoles in the treatment of a disease or condition mediated by MCP-1.Type: GrantFiled: February 3, 2000Date of Patent: September 11, 2001Assignee: Zeneca LimitedInventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
-
Patent number: 6015814Abstract: The invention concerns derivatives of the formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is amino-(2-4C)alkylamino, (1-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino,di-[(1-4C)alkyl]amino-(2-4C) alkylamino, pyrrolidin-1-yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alkylamino, piperazin-1-yl-(2-4C)alkylamino, or 4-(1-4C) alkylpiperazin-1-yl-(2-4C)alkylamino, or pharmaceutically acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.Type: GrantFiled: September 26, 1997Date of Patent: January 18, 2000Assignee: Zeneca LimitedInventor: Andrew John Barker
-
Patent number: 5955464Abstract: The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy;n is 1, 2 or 3;each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.Type: GrantFiled: May 22, 1997Date of Patent: September 21, 1999Assignee: Zeneca LimitedInventor: Andrew John Barker
-
Patent number: 5952333Abstract: The invention concerns the quinazoline derivative 6-(2-methoxyethylamino)-7-methoxy-4-(3'-methylanilino)quinazoline, or a pharmaceutically-acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing the compound and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatments of proliferative disease such as cancer.Type: GrantFiled: September 26, 1997Date of Patent: September 14, 1999Assignee: Zeneca LimitedInventor: Andrew John Barker
-
Patent number: 5942514Abstract: The invention concerns quinazoline derivatives of formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is 1-4C)alkoxy-(2-4C)alkylamino; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.Type: GrantFiled: September 26, 1997Date of Patent: August 24, 1999Assignee: Zeneca LimitedInventor: Andrew John Barker
-
Patent number: 5866572Abstract: The invention concerns quinazoline derivatives of the formula I ##STR1## wherein X.sup.1 is a direct link or a group such as CO, C(R.sup.2).sub.2 and CH(OR.sup.2);wherein Q.sup.1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; andwherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.Type: GrantFiled: February 13, 1997Date of Patent: February 2, 1999Assignee: Zeneca LimitedInventors: Andrew John Barker, Craig Johnstone
-
Patent number: 5814630Abstract: The invention concerns quinazoline compounds of the formula I ##STR1## wherein Q.sup.1 is a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl;and wherein Q.sup.2 is phenyl which optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.Type: GrantFiled: February 13, 1997Date of Patent: September 29, 1998Assignee: Zeneca LimitedInventors: Andrew John Barker, Craig Johnstone